Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

@inproceedings{Weller2016CilengitideIN,
  title={Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome},
  author={Michael Weller and Louis Burt Nabors and Thierry Gorlia and Henning Leske and Elisabeth Jane Rushing and Pierre Bady and Christine Hicking and J. Randolph Perry and Y. G. Hong and Patrick Roth and Wolfgang Wick and Simon L Goodman and Monika E Hegi and Martin Picard and Holger Moch and Josef Straub and Roger Stupp},
  booktitle={Oncotarget},
  year={2016}
}
Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, potentially by modulating activation of the transforming growth factor (TGF)-β pathway. The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed glioblastoma with versus without O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. These trials failed to meet their primary endpoints.Immunohistochemistry was used to assess the… CONTINUE READING
Highly Cited
This paper has 36 citations. REVIEW CITATIONS
11 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…